WO2004093995A3 - Use of antioxidants to treat bone loss disorders - Google Patents

Use of antioxidants to treat bone loss disorders Download PDF

Info

Publication number
WO2004093995A3
WO2004093995A3 PCT/GB2004/001695 GB2004001695W WO2004093995A3 WO 2004093995 A3 WO2004093995 A3 WO 2004093995A3 GB 2004001695 W GB2004001695 W GB 2004001695W WO 2004093995 A3 WO2004093995 A3 WO 2004093995A3
Authority
WO
WIPO (PCT)
Prior art keywords
bone loss
antioxidants
loss disorders
treat bone
antioxidant
Prior art date
Application number
PCT/GB2004/001695
Other languages
French (fr)
Other versions
WO2004093995A2 (en
Inventor
Timothy John Chambers
Karen Fuller
Christopher John Jagger
Jenny Maree Lean
Original Assignee
St Georges Entpr Ltd
Timothy John Chambers
Karen Fuller
Christopher John Jagger
Jenny Maree Lean
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Georges Entpr Ltd, Timothy John Chambers, Karen Fuller, Christopher John Jagger, Jenny Maree Lean filed Critical St Georges Entpr Ltd
Publication of WO2004093995A2 publication Critical patent/WO2004093995A2/en
Publication of WO2004093995A3 publication Critical patent/WO2004093995A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations

Abstract

Bone loss disorders can be treated or prevented by administration of an agent which increases the levels of oxidant defences and/or at least one antioxidant in a subject. The agent can be an antioxidant and may act either directly to increase antioxidant levels and/or oxidant defences or indirectly.
PCT/GB2004/001695 2003-04-17 2004-04-19 Use of antioxidants to treat bone loss disorders WO2004093995A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0308952.1 2003-04-17
GBGB0308952.1A GB0308952D0 (en) 2003-04-17 2003-04-17 Method

Publications (2)

Publication Number Publication Date
WO2004093995A2 WO2004093995A2 (en) 2004-11-04
WO2004093995A3 true WO2004093995A3 (en) 2005-04-21

Family

ID=9956987

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/001695 WO2004093995A2 (en) 2003-04-17 2004-04-19 Use of antioxidants to treat bone loss disorders

Country Status (2)

Country Link
GB (1) GB0308952D0 (en)
WO (1) WO2004093995A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8669282B2 (en) * 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
WO2006024096A1 (en) * 2004-08-31 2006-03-09 Chemgenex Pharmaceuticals Limited Method for modulating osteoclastogenesis
US7956031B2 (en) 2005-05-31 2011-06-07 Naidu Lp Metallo-lactoferrin-coenzyme compositions for trigger and release of bioenergy
WO2007080630A1 (en) * 2006-01-10 2007-07-19 Masayoshi Yamaguchi AGENT FOR INCREASING BONE MINERAL CONTENT COMPRISING p-HYDROXYCINNAMIC ACID AS ACTIVE INGREDIENT
US8021659B2 (en) 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
US20100015085A1 (en) * 2006-05-01 2010-01-21 Johns Hopkins University Phase 2 inducers and related signaling pathways protect cartilage against inflammation/infection, apoptosis and stress
WO2008013900A2 (en) * 2006-07-26 2008-01-31 The Regents Of The University Of California Osteogenic enhancer composition
GB0704718D0 (en) * 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
US20100303888A1 (en) * 2007-04-18 2010-12-02 Jake Barralet Composition for enhancing bone formation
ITMI20080172A1 (en) * 2008-02-05 2009-08-06 Bios Line Spa ORAL FORMULATIONS FOR PROTECTION OF RESPIRATORY PATHWAYS WITH SPECIAL REFERENCE TO INFLAMMATORY AND NEOPLASTIC PHENOMENA
GB0811992D0 (en) * 2008-07-01 2008-08-06 Mithen Richard Treatment
EP2367549B1 (en) * 2008-12-30 2013-08-28 Hill's Pet Nutrition, Inc. Use of alpha-lipoic acid for treating or preventing degenerative joint conditions, osteoarthritis, cartilage damage, and related disorders in companion animals
KR101169850B1 (en) * 2008-12-30 2012-07-30 서울대학교산학협력단 A pharmaceutical composition for preventing and treating bone metabolic disease or metastatic cancer by bone metastasis comprising Trolox
WO2013031620A1 (en) * 2011-08-26 2013-03-07 国立大学法人名古屋大学 Osteogenesis promoter and use thereof
EP3310372A4 (en) * 2015-05-19 2019-03-06 Mayo Foundation For Medical Education And Research Methods and materials for promoting bone formation
EP3400025B1 (en) 2016-01-06 2024-03-13 The Trustees of Columbia University in the City of New York The use of guaiacol for the prevention and treatment of glycogen storage disease
EP3593638A1 (en) * 2018-07-09 2020-01-15 Université de Lausanne Fungicides to prevent and control fungal pathogens
CN112089719A (en) * 2020-09-07 2020-12-18 广州中医药大学第一附属医院 Application of troxerutin in preparation of bone formation related medicines
CN112972475A (en) * 2021-03-24 2021-06-18 南京医科大学友谊整形外科医院有限责任公司 Application of oltipraz in preparation of product for preventing and treating osteoporosis

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590067A (en) * 1984-10-18 1986-05-20 Peritain, Ltd. Treatment for periodontal disease
JPH0687750A (en) * 1992-09-08 1994-03-29 Taiyo Yakuhin Kogyo Kk Medicine composition
JPH0840888A (en) * 1994-07-28 1996-02-13 Ajinomoto Co Inc Antitumor agent against myeloma-based tumor
JPH0881380A (en) * 1994-09-09 1996-03-26 Suntory Ltd Anti-periodontitis agent and anti-periodontitis food containing high-molecular weight polyphenol as active component
JPH11130644A (en) * 1997-10-29 1999-05-18 Lion Corp Composition for oral cavity
CA2012208C (en) * 1989-03-27 2001-05-22 Julius Ozick Method of treating periodontitis
US20020048798A1 (en) * 2000-03-15 2002-04-25 Avery Mitchell Allen Novel antioxidants
EP1214893A1 (en) * 2000-12-16 2002-06-19 Aventis Pharma Deutschland GmbH Health promoting compositions
EP1431385A1 (en) * 2002-12-18 2004-06-23 Döhler GmbH Xanthohumol containing beverage

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590067A (en) * 1984-10-18 1986-05-20 Peritain, Ltd. Treatment for periodontal disease
CA2012208C (en) * 1989-03-27 2001-05-22 Julius Ozick Method of treating periodontitis
JPH0687750A (en) * 1992-09-08 1994-03-29 Taiyo Yakuhin Kogyo Kk Medicine composition
JPH0840888A (en) * 1994-07-28 1996-02-13 Ajinomoto Co Inc Antitumor agent against myeloma-based tumor
JPH0881380A (en) * 1994-09-09 1996-03-26 Suntory Ltd Anti-periodontitis agent and anti-periodontitis food containing high-molecular weight polyphenol as active component
JPH11130644A (en) * 1997-10-29 1999-05-18 Lion Corp Composition for oral cavity
US20020048798A1 (en) * 2000-03-15 2002-04-25 Avery Mitchell Allen Novel antioxidants
EP1214893A1 (en) * 2000-12-16 2002-06-19 Aventis Pharma Deutschland GmbH Health promoting compositions
EP1431385A1 (en) * 2002-12-18 2004-06-23 Döhler GmbH Xanthohumol containing beverage

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1994, HANIOKA T ET AL: "Effect of topical application of Coenzyme Q10 on adult periodontitis", XP002291089, Database accession no. EMB-1995041314 *
HALL T J ET AL: "THE ROLE OF REACTIVE OXYGEN INTERMEDIATES IN OSTEOCLASTIC BONE RESORPTION", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 207, no. 1, 6 February 1995 (1995-02-06), pages 280 - 287, XP002068360, ISSN: 0006-291X *
MOLECULAR ASPECTS OF MEDICINE 1994 UNITED KINGDOM, vol. 15, no. SUPPL., 1994, pages S241 - S248, ISSN: 0098-2997 *
NAKAMUTA HIROMICHI ET AL: "A novel bone-protective effect of taurine on low Ca diet-induced osteoporosis in rats", JAPANESE JOURNAL OF PHARMACOLOGY, vol. 88, no. Supplement 1, 2002, & 75TH ANNUAL MEETING OF THE JAPANESE PHARMACOLOGICAL SOCIETY; KUMAMOTO, JAPAN; MARCH 13-15, 2002, pages 108P, XP009034443, ISSN: 0021-5198 *
PATENT ABSTRACTS OF JAPAN vol. 0183, no. 47 (C - 1219) 30 June 1994 (1994-06-30) *
PATENT ABSTRACTS OF JAPAN vol. 1996, no. 06 28 June 1996 (1996-06-28) *
PATENT ABSTRACTS OF JAPAN vol. 1996, no. 07 31 July 1996 (1996-07-31) *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 10 31 August 1999 (1999-08-31) *

Also Published As

Publication number Publication date
WO2004093995A2 (en) 2004-11-04
GB0308952D0 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
WO2004093995A3 (en) Use of antioxidants to treat bone loss disorders
WO2005034998A3 (en) Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2007073505A3 (en) Trpa1 inhibitors for treating pain
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
WO2005079143A3 (en) Topical formulations for the treatment of skin conditions
EP1622589A4 (en) Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
GB2434983A (en) Methods and compositions for wound healing
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2005065667A3 (en) Compositions for treating or preventing obesity and insulin resistance disorders
EP2100612A3 (en) Semi-solid mucoadhesive formulations
PL1682126T3 (en) Substituted benzazoles and use thereof as inhibitors of raf kinase
WO2004006853A3 (en) Treatment and prophylaxis with 4-1bb-binding agents
EP1701715A4 (en) Zeaxanthin formulations with additional ocular-active nutriente, for protecting eye health and treating eye disorders
HK1121936A1 (en) Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
UA86345C2 (en) Normal;heading 1;heading 2;USE OF OSTEOPROTEGERIN FOR THE PREVENTION AND/OR TREATMENT OF FIBROSIS
WO2004069181A3 (en) Composition for the treatment of intraocular pressure
WO2004103283A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
WO2007079312A3 (en) Compositions and methods for treating actin-mediated medical conditions
TW200500077A (en) Antioxidant-containing wipes and absorbent products for improving skin health
WO2004064719A3 (en) Synergistic compositions and methods for potentiating anti-oxidative activity
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
TW200505437A (en) Composition possessing autonomic nerve function regulating action and use thereof
MY122838A (en) Treating allergic and inflammatory conditions
WO2004093813A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
WO2006116374A3 (en) Surface treatments for promoting selective tissue attachment to medical implants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase